Nuclidium is a clinical-stage biotechnology company specializing in the development of next-generation copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer treatment

Leveraging its proprietary CuTrace™ platform, Nuclidium utilizes copper isotopes to create a unified diagnostic-to-therapeutic approach. This platform aims to overcome existing limitations in radiotheranostics, offering scalable, accessible, and clinically superior solutions for patients worldwide. 

Nuclidium's lead compounds, including NuriPro™ and TraceNET™, are currently undergoing clinical evaluation for various oncology indications.